21st.BIO has now granted access to its precision fermentation technology platform to ingredient manufacturers enabling the production of dairy proteins at competitive cost. This follows 21st.BIO’s successful scaling of the beta-lactoglobulin protein, a major protein in milk that provides highly valuable nutrition and textural components of milk and other dairy ingredients.

By offering its precision fermentation technology platform widely, 21st.BIO mitigates the cost and time associated with development, opening access to proven industrial-scale production technology for precision fermentation of alternative proteins. The platform provides a sustainable and less carbon and resource-intensive alternative to traditional animal-based production methods and helps to stabilize global food supply chains. According to recent studies, producing proteins via precision fermentation reduces greenhouse gases (GHG) emissions, and land and water use by 90 to 96%, compared to animal-derived production.

With 21st.BIO’s platform, customers have access to world-leading industrial production strains, and fermentation processes, as well as support with scale-up, tech transfers to contract manufacturers, and regulatory approvals to get to market at speed and with lower costs. 21st.BIO continuously optimizes the strains and processes, ensuring customers are always ahead of the market.

21st.BIO has the most advanced precision fermentation technology platform in the industry for large-scale production. The technology foundation is licensed from Novozymes, which has 40 years of experience perfecting production strains and processes for industrial production. The technology base is already used to provide dozens of food-grade products on the market today.

21st.BIO’s technology can be optimized for each customer’s specific purpose, such as the nutritional fortification of a plant-based product, improvement of texture in alternative dairy, and medical nutrition.

Customers of 21st.BIO can be innovative start-ups planning to take one or several proteins to the market, as well as established players expanding into sustainable alternatives, and dairy companies aiming to grow with the increasing global demand for proteins while reducing their footprint on the environment.

With a technology platform based on Novonesis (formerly known as Novozymes), and financing from Novo Holdings, 21st.BIO is uniquely positioned to help accelerate the quest for greener and more nutritious alternatives in the food industry.

Visit 21st.bio or connect directly using the Request Information button below.